Tumor-infiltrating lymphocytes have been reported to be associated with response to neoadjuvant chemotherapy and survival in breast cancer (BC) patients. However, little is known about the value of peripheral blood parameter in predicting the prognosis in BC.
Methods:
In this study, parameters of complete blood count from 417 BC patients with a median 7.6-year follow-up after surgery were collected and correlated with patient survival.
Results:
It was found that leukocyte counts were positively correlated with disease-free survival (DFS, p = 0.016) and overall survival (OS, p = 0.014), whereas platelet counts were negatively correlated with DFS (p = 0.003) and OS (p = 0.082) in BC. Leukocyte and platelet counts were independent prognostic factors for the BC patient survival. Besides, the prognostic value of leukocyte and platelet counts was further evaluated in the BC patients with different molecular subtypes. Together, BC patients with high leukocyte counts and low platelet counts had better DFS (p = 0.001) and OS (p = 0.017) than the other patients.
Conclusion:
Parameters of complete blood count could be acquired easily and serve as cost-effective prognostic biomarkers in BC.
Get full access to this article
View all access options for this article.
References
1.
ChenY, ChenK, XiaoX, et al.Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: A retrospective study. BMC Cancer, 2016; 16:320.
2.
NohH, EommM, HanA. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer, 2013; 16:55.
3.
Marin HernandezC, Pinero MadronaA, Gil VazquezPJ, et al.Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. Clin Transl Oncol, 2018; 20:476.
4.
TesfamariamB. Involvement of platelets in tumor cell metastasis. Pharmacol Ther, 2016; 157:112.
5.
TempletonAJ, McNamaraMG, SerugaB, et al.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J Natl Cancer Inst, 2014; 106:dju124.
6.
WarissBR, de Souza AbrahãoK, de AguiarSS, et al.Effectiveness of four inflammatory markers in predicting prognosis in 2374 women with breast cancer. Maturitas, 2017; 101:51.
7.
ElyasiniaF, KeramatiMR, AhmadiF, et al.Neutrophil-lymphocyte ratio in different stages of breast cancer. Acta Med Iran, 2017; 55:228.
8.
GrazianoV, GrassadoniaA, IezziL, et al.Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast, 2019; 44:33.
9.
XuJ, NiC, MaC, et al.Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy. Clin Transl Oncol, 2017; 19:989.
10.
MantasD, KostakisID, MachairasN, et al.White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma. Oncol Lett, 2016; 12:1610.
11.
OrdituraM, GaliziaG, DianaA, et al.Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis. ESMO Open, 2016; 1:e000038.
12.
Ramos-EsquivelA, Rodriguez-PorrasL, PorrasJ. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in non-metastatic breast cancer patients from a Hispanic population. Breast Dis, 2017; 37:1.
13.
AkinbamiA, PopoolaA, AdediranA, et al.Full blood count pattern of pre-chemotherapy breast cancer patients in Lagos, Nigeria. Caspian J Intern Med, 2013; 4:574.
14.
BudcziesJ, KlauschenF, SinnBV, et al.Cutoff finder: A comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One, 2012; 7:e51862.
15.
ChenTM, LinCC, HuangPT, et al.Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol, 2012; 27:553.
16.
ChoH, HurHW, KimSW, et al.Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother, 2009; 58:15.
17.
LabelleM, BegumS, HynesRO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell, 2011; 20:576.
18.
CamererE, QaziAA, DuongDN, et al.Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood, 2004; 104:397.
19.
De LarcoJE, WuertzBR, FurchtLT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res, 2004; 10:4895.
20.
MullerI, MunderM, KropfP, et al.Polymorphonuclear neutrophils and T lymphocytes: Strange bedfellows or brothers in arms?. Trends Immunol, 2009; 30:522.
21.
HalazunKJ, HardyMA, RanaAA, et al.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg, 2009; 250:141.
22.
AzabB, BhattVR, PhookanJ, et al.Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol, 2012; 19:217.
23.
BakewellSJ, NestorP, PrasadS, et al.Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A, 2003; 100:14205.
24.
SchumacherD, StrilicB, SivarajKK, et al.Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell, 2013; 24:130.
25.
DentR, TrudeauM, PritchardKI, et al.Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res, 2007; 13:4429.
26.
LiedtkeC, MazouniC, HessKR, et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 2008; 26:1275.
27.
DenkertC, LoiblS, NoskeA, et al.Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol, 2010; 28:105.
28.
DenkertC, von MinckwitzG, BraseJC, et al.Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol, 2015; 33:983.
29.
LoiS, SirtaineN, PietteF, et al.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol, 2013; 31:860.
30.
Ingold HeppnerB, UntchM, DenkertC, et al.Tumor-infiltrating lymphocytes: A predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer. Clin Cancer Res, 2016; 22:5747.
31.
SalgadoR, DenkertC, CampbellC, et al.Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO trial. JAMA Oncol, 2015; 1:448.
32.
LoiS, MichielsS, SalgadoR, et al.Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol, 2014; 25:1544.
33.
MiyashitaM, SasanoH, TamakiK, et al.Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: A retrospective multicenter study. Breast Cancer Res, 2015; 17:124.
34.
AdamsS, GrayRJ, DemariaS, et al.Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol, 2014; 32:2959.
35.
ZitvogelL, KroemerG. The immune response against dying tumor cells: Avoid disaster, achieve cure. Cell Death Differ, 2008; 15:1.
36.
ApetohL, GhiringhelliF, TesniereA, et al.The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev, 2007; 220:47.
37.
CoffeltSB, KerstenK, DoornebalCW, et al.IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature, 2015; 522:345.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
